Journal List > Korean J Pediatr Gastroenterol Nutr > v.13(Suppl 1) > 1043493

Lee, Oh, and Kim: The Principles of Drug Therapy of Crohn's Disease in Child and Adolescent


Crohn's disease (CD) is a chronic, relapsing disorder of unknown etiology and which affects patients for their entire life. Pediatric CD is significant in that approximately 25% of inflammatory bowel disease (IBD) patients are diagnosed as children and adolescents. The incidence continues to rise rapidly, but has not yet plateaued in Korea. The other important issues of pediatric CD are growth impairment and pubertal delay, both of which may result in permanent problems and which should be considered as one of the important aspects of treatment in contrast to that seen in adult patients. This review article presents pediatric clinicians with the basic principles of the medical treatment of Crohn's disease as it presents in childhood and adolescence. The goal of treatment in pediatric Crohn's disease is to achieve physical and psychological remission which includes freedom from abdominal pain, hematochezia, anemia, luminal inflammation, maintaining the normal value of albumin and inflammatory markers, stopping the use of corticosteroids, achieving normal growth and puberty, and also maintaining optimal mental health. We extensively reviewed the current studies in addition to conventional treatments which include 5-ASA, nutritional therapy, antibiotics, immunosuppressants, and anti-TNF-alpha blockades. We also attempted to consider the specific treatment of luminal and fistulizing disease, management in postoperative situations, and the optimal management strategy in order to maintain normal physical growth.

Figures and Tables

Table 1
Treatment Indications, Side Effects and Remarks for Various Medications


1. Barton JR, Gillon S, Ferguson A. Incidence of inflammatory bowel disease in Scottish children between 1968 and 1983; marginal fall in ulcerative colitis, three-fold rise in Crohn's disease. Gut. 1989. 30:618–622.
2. Askling J, Grahnquist L, Ekbom A, Finkel Y. Incidence of paediatric Crohn's disease in Stockholm, Sweden. Lancet. 1999. 354:1179.
3. Kolek A, Janout V, Tichy M, Grepl M. The incidence of inflammatory bowel disease is increasing among children 15 years old and younger in the Czech Republic. J Pediatr Gastroenterol Nutr. 2004. 38:362–363.
4. Yang SK, Yun S, Kim JH, Park JY, Kim HY, Kim YH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: A KASID study. Inflamm Bowel Dis. 2008. 14:542–549.
5. Kim BJ, Song SM, Kim KM, Lee YJ, Rhee KW, Jang JY, et al. Characteristics and trends in the incidence of inflammatory bowel disease in Korean children: a single-center experience. Dig Dis Sci. 2010. 55:1989–1995.
6. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007. 448:427–434.
7. Jang JY, Song SM, Kim KM, Oh SH, Lee YJ, Rhee KW. Lack of common NOD2 mutations in korean pediatric patients with inflammatory bowel disease. Pediatr Int. 2010. 52:888–889.
8. Markowitz J, Grancher K, Mandel F, Daum F. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Am J Gastroenterol. 1993. 88:44–48.
9. Song SM, Jang JY, Kim KM. Nutritional status of childhood onset inflammatory bowel disease. Clin Nutr Suppl. 2008. 3:196.
10. Kim KM. The pharmacotherapy of inflammatory bowel disease in child and adolescence. J Korean Med Assoc. 2010. 53:524–530.
11. Benchimol EI, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2008. CD006792.
12. Hyams JS, Markowitz JF. Can we alter the natural history of Crohn disease in children? J Pediatr Gastroenterol Nutr. 2005. 40:262–272.
13. Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2008. CD000296.
14. Suh HA, Kim SE, Jang JY, Kim BJ, Kim JS, Lee SY, et al. Efficacy of nutritional therapy in children with crohn disease. Korean J Pediatr Gastroenterol Nutr. 2006. 9:210–217.
15. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2007. CD000542.
16. Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr. 2000. 31:8–15.
17. Gonzalez-Huix F, de Leon R, Fernandez-Banares F, Esteve M, Cabre E, Acero D, et al. Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial. Gut. 1993. 34:778–782.
18. Lochs H, Allison SP, Meier R, Pirlich M, Kondrup J, Schneider S, et al. Introductory to the ESPEN guidelines on enteral nutrition: terminology, definitions and general topics. Clin Nutr. 2006. 25:180–186.
19. Hanauer SB, Stromberg U. Oral pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004. 2:379–388.
20. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2004. CD003574.
21. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999. 340:1398–1405.
22. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006. 130:323–333. quiz 591.
23. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007. 146:829–838.
24. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med. 2005. 72:250–256.
25. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003. 98:1315–1324.
26. Veres G, Baldassano RN, Mamula P. Infliximab therapy in children and adolescents with inflammatory bowel disease. Drugs. 2007. 67:1703–1723.
27. Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003. MMWR Morb Mortal Wkly Rep. 2004. 53:683–686.
28. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002. 359:1541–1549.
29. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003. 348:601–608.
30. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med. 1997. 337:1029–1035.
31. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev. 2000. CD000545.
32. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995. 123:132–142.
33. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2009. CD000545.
34. Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet. 2007. 46:187–208.
35. Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2004. 2:410–417.
36. Cunliffe RN, Scott BB. Review article: monitoring for drug side-effects in inflammatory bowel disease. Aliment Pharmacol Ther. 2002. 16:647–662.
37. Wallace TM, Veldhuyzen van Zanten SJ. Frequency of use and standards of care for the use of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease: a systematic review of the literature and a survey of Canadian gastroenterologists. Can J Gastroenterol. 2001. 15:21–28.
38. Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut. 1996. 39:401–406.
39. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev. 2005. CD003459.
40. Uhlen S, Belbouab R, Narebski K, Goulet O, Schmitz J, Cezard JP, et al. Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. Inflamm Bowel Dis. 2006. 12:1053–1057.
41. Andersson P, Olaison G, Bendtsen P, Myrelid P, Sjodahl R. Health related quality of life in Crohn's proctocolitis does not differ from a general population when in remission. Colorectal Dis. 2003. 5:56–62.
42. Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2003. CD000301.
43. Simms L, Steinhart AH. Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2001. CD002913.
44. Sandborn WJ, Lofberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005. 100:1780–1787.
45. Akobeng AK, Thomas AG. Enteral nutrition for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2007. CD005984.
46. Wilschanski M, Sherman P, Pencharz P, Davis L, Corey M, Griffiths A. Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. Gut. 1996. 38:543–548.
47. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Cochrane Database Syst Rev. 2005. CD003715.
48. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007. 132:863–873. quiz 1165-6.
49. De Bie CI, Hummel TZ, Kindermann A, Kokke FT, Damen GM, Kneepkens CM, et al. The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited. Aliment Pharmacol Ther. 2011. 33:243–250.
50. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010. 362:1383–1395.
51. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007. 132:52–65.
52. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev. 2000. CD000067.
53. Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, et al. North American Crohn's Study Group Investigators. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med. 2000. 342:1627–1632.
54. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2006. CD004826.
55. Turner D, Zlotkin SH, Shah PS, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2007. CD006320.
56. Dignass AU. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Current Management. J Crohns Colitis. 2010. 4:28–62.
57. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004. 126:402–413.
58. Sands BE, Blank MA, Patel K, van Deventer SJ. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004. 2:912–920.
59. Panaccione R, Colombel JF, Sandborn WJ, Rutgeerts P, D'Haens GR, Robinson AM, et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2010. 31:1296–1309.
60. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007. 369:1641–1657.
61. Schwartz DA, Loftus EV Jr, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002. 122:875–880.
62. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980. 302:981–987.
63. Kader HA, Raynor SC, Young R, Kaufman SS, Vanderhoof J, Ruby EI, et al. Introduction of 6-mercaptopurine in Crohn's disease patients during the perioperative period: a preliminary evaluation of recurrence of disease. J Pediatr Gastroenterol Nutr. 1997. 25:93–97.
64. Besnard M, Jaby O, Mougenot JF, Ferkdadji L, Debrun A, Faure C, et al. Postoperative outcome of Crohn's disease in 30 children. Gut. 1998. 43:634–638.
65. Brignola C, Cottone M, Pera A, Ardizzone S, Scribano ML, De Franchis R, et al. Italian Cooperative Study Group. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Gastroenterology. 1995. 108:345–349.
66. McLeod RS, Wolff BG, Steinhart AH, Carryer PW, O'Rourke K, Andrews DF, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology. 1995. 109:404–413.
67. Cottone M, Camma C. Mesalamine and relapse prevention in Crohn's disease. Gastroenterology. 2000. 119:597.
68. Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004. 127:723–729.
69. Ardizzone S, Maconi G, Sampietro GM, Russo A, Radice E, Colombo E, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology. 2004. 127:730–740.
70. Sinitsky DM, Lemberg DA, Leach ST, Bohane TD, Jackson R, Day AS. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease. J Gastroenterol Hepatol. 2010. 25:810–816.
71. Thayu M, Denson LA, Shults J, Zemel BS, Burnham JM, Baldassano RN, et al. Determinants of changes in linear growth and body composition in incident pediatric Crohn's disease. Gastroenterology. 2010. 139:430–438.
Similar articles